Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy

Inclusion Criteria: * Fully understood and voluntarily signed the informed Consent Form (ICF); * Age: \> 18 (at the time of signing the informed consent form); Gender is not limited. * Preoperative eGFR \> 45ml/min/1.73m2 (corrected CKD-EPI formula); * After the clinician formulates the treatment plan and communicates with the patient, they decide whether to perform radical nephrectomy or partial nephrectomy. * ECOG score: 0-2 points; * Be willing and able to abide by the visits, treatments, laboratory tests and other procedures of the research plan. Exclusion Criteria: * Patients with solitary kidney or severe contralateral renal insufficiency (eGFR \< 15ml/min/1.73m2); * Preoperative reliance on renal replacement therapy (such as dialysis, etc.); * Those who fail to complete the nephrectomy as planned during the operation; * Patients with lymph node metastasis, distant metastasis or venous tumor thrombus; * The healthy kidney has undergone radiotherapy, ablation or other surgeries. * Have a history of allergy to ultrasound contrast agents; * Have any contraindications for contrast-enhanced ultrasound, such as right-to-left shunt, severe pulmonary hypertension, etc. * Patients with hemodynamic instability, including those with persistent hypotension (blood pressure \< 90/60 MMHG), uncontrollable heart failure, active bleeding (such as gastrointestinal and cerebral hemorrhage, etc.), or those with a bleeding tendency and hemoglobin \< 60g/L and/or platelet count \< 50×109/L; * Accompanied by structural abnormalities of the urinary system or functional abnormalities that cannot be corrected in a short time (such as duplicate kidneys, polycystic kidneys, horseshoe kidneys, isolated kidneys, renal artery stenosis \> 50%, urinary tract obstruction, and previous history of kidney surgery, etc.), long-term indwelling of urinary catheters, etc. * There are other diseases that limit life expectancy to less than six months; * Previous (≤30 days before randomization) or concurrent participation in another clinical study.